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ABSTRACT
Background. Cytoreductive surgery (CRS) and intraperi-
toneal chemotherapy (IPC) is an established therapy for
pseudomyxoma peritonei (PMP). However, the role of IPC
is unclear. By ex vivo assessment of PMP tumor cell
sensitivity to cytotoxic drugs, we investigated the basis for
IPC drug selection and the role of IPC in the management
of PMP.
Methods. Tumor cells were prepared by collagenase
digestion of tumor tissue from 133 PMP patients planned
for CRS and IPC. Tumor cell sensitivity to oxaliplatin,
5FU, mitomycin C, doxorubicin, irinotecan, and cisplatin
was assessed in a 72-h cell-viability assay. Drug sensitivity
was correlated to progression-free survival (PFS) and
overall survival (OS).
Results. Samples from 92 patients were analyzed success-
fully. Drug sensitivity varied considerably between samples.
Peritoneal mucinous carcinomatosis (PMCA), compared
with PMCA intermediate or disseminated peritoneal ade-
nomucinosis, was slightly more resistant to platinum and
5FU and tumor cells from patients previously treated with
chemotherapy were generally less sensitive than those from
untreated patients. Multivariate analysis showed patient
performance status and completeness of CRS to be
prognostic for OS. Among patients with complete CRS
(n = 61), PFS tended to be associated with sensitivity to
mitomycin C and cisplatin (p & 0.06). At the highest drug
concentration tested, the hazard ratio for disease relapse
increased stepwise with drug resistance for all drugs.
Conclusions. Ex vivo assessment of drug sensitivity in
PMP provides prognostic information. The results suggest
a role for IPC as therapeutic adjunct to CRS and for indi-
vidualization of IPC by pretreatment assessment of drug
sensitivity.
Pseudomyxoma peritonei (PMP) is a rare tumor disease
characterized by disseminated mucus and mucinous tumor
tissue implants on the peritoneal surfaces, now considered
to originate from the appendix.1 By use of cytoreductive
surgery (CRS) combined with intraperitoneal chemother-
apy (IPC), as introduced by Sugarbaker, with the IPC now
mostly being hyperthermic (HIPEC), the prognosis has
improved.2 Thus, experienced centres report a 5-year
overall survival (OS) in the range of 70–95 % compared
with 30–40 % often reported for the strategy of debulking
surgery.3–5 The main factors associated with favorable
prognosis are complete CRS, low tumor load, and low
histological grade.5
Systemic chemotherapy alone as treatment of PMP has
not been extensively investigated but seems poorly active
in this disease.6 However, the role of the chemotherapy
part of the CRS and IPC treatment package in PMP is
unclear. Thus, the effect of CRS with or without IPC has
not been directly compared and long-term survival has
been reported with CRS alone.5,7,8
In contrast, IPC provides clinical benefit as adjunct to
CRS in peritoneal carcinomatosis from gastric and ovarian
cancer.8,9 Furthermore, IPC in PMP differs between
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treatment centres in terms of drug selection, dosing, and
timing of the IPC.8,10 Thus, IPC as part of treatment of
PMP is in need of further investigation to define its role and
provide a basis for how to optimize this resource
demanding treatment step.
We used a short-term ex vivo assay to evaluate the
tumor cell sensitivity to cytotoxic drugs in samples from
PMP patients undergoing CRS and IPC. The goals were to
provide information on the pattern of drug activity in PMP
and to correlate the ex vivo drug sensitivity pattern to the
clinical outcome.
METHODS
Patients and Tumor Samples
A total of 133 patients scheduled for CRS and HIPEC
for PMP at the Department of Surgery, Uppsala University
Hospital between May 2006 and December 2011, and from
which a tumor sample for ex vivo assessment of drug
activity was obtained, formed the basis for the study.
Tumor sampling was performed intraoperatively prior to
HIPEC, which consisted of 30–35 mg/m2 of mitomycin C,
100 mg/m2 of cisplatin combined with 15 mg/m2 of dox-
orubicin or 360 mg/m2 of both irinotecan and oxaliplatin.4
Tumor sampling and data collection was based on patient
informed consent and approved by the Regional Ethical
Review Board in Uppsala (Dnr 2007/237). None of the
patients had adjuvant systemic chemotherapy following
CRS and HIPEC.
Tumor histopathology was classified as disseminated
peritoneal adenomucinosis (DPAM), peritoneal mucinous
carcinomatosis (PMCA), or PMCA with intermediate fea-
tures.11 Tumor load was assessed as the Peritoneal Cancer
Index (PCI) at time of surgery.12 Residual disease after a
maximal surgical effort was quantified according to the
completeness of cytoreduction score (CC). CC scores 0 (no
macroscopic tumor left) and 1 (residual tumor\0.25 cm)
were considered as complete cytoreduction.13
Ex Vivo Assessment of Drug Sensitivity
The tumor specimen was kept in buffer at 6 C until
preparation. Tumor cells were prepared by collagenase
digestion as described.14 The cells obtained were mostly
single cells or small cell clusters with C90 % viability and
with\30 % contaminating nonmalignant cells, as judged
by morphological examinations of May-Gru¨nwald-
Giemsa-stained cytocentrifugate preparations.
The drugs used for HIPEC (see above) were tested
ex vivo. In addition, 5FU, an established drug in gas-
trointestinal cancer treatment, was included. All drugs were
from commercially available clinical preparations. The
drugs were tested at three tenfold dilutions from the max-
imal concentration (lM) of 100 for cisplatin, 100 for
oxaliplatin, 10 for doxorubicin, 1000 for 5FU, 100 for
mitomycin C, and 1000 for irinotecan. The drug concen-
trations used ex vivo are chosen empirically to produce
concentration—response curves allowing for extraction of
50 % inhibitory concentrations (IC50), i.e., the drug con-
centration producing a cell survival of 50 % compared with
an unexposed control. The maximal concentrations used
ex vivo are close to Cmax achievable during IPC for most
drugs.15 384-well microplates (Nunc) were prepared with
5-ll drug solution at 109 the final drug concentration using
the pipetting robot BioMek 2000 (Beckman Coulter). The
plates were then stored at -70 C until further use.
The semiautomated fluorometric microculture cytotoxi-
city assay (FMCA) was used to assess drug sensitivity.16
Briefly, tumor cells from patient samples (5000 cells/well
in 45 ll culture medium RPMI 1640 (supplemented with
10 % foetal calf serum, glutamine and antibiotics) were
seeded in the drug-prepared 384-well plates using the
pipetting robot Precision 2000 (Bio-Tek Instruments Inc.,
Winooski, VT). Three columns without drugs served as
controls and one column with medium only served as
blank.
The culture plates were incubated at 37 C in humidified
atmosphere containing 95 % air and 5 % CO2. After 72 h
incubation, the culture medium was washed away and
50 ll/well of a physiological buffer containing 10 lg/ml of
the vital dye fluorescein diacetate (FDA) were added to
control, experimental, and blank wells. After incubation for
30–45 min at 37 C, the fluorescence from each well was
read in a FluoroScan 2 (Labsystems OY, Helsinki,
Finland).
Quality criteria for a successful assay were: C70 %
tumor cells in the cell preparation before incubation and/or
on the assay day, a fluorescence signal in control cultures
of C5 x mean blank values, and a coefficient of variation of
cell survival in control cultures of B30 %. The results
obtained by the viability indicator FDA are calculated as
survival index (SI), defined as the fluorescence of the test
expressed as a percentage of control cultures, with blank
values subtracted.
Patient Data and Follow-Up
Clinical data relevant for the study were retrieved from
the patient files. Patients with complete cytoreduction were
followed for progression-free survival (PFS) by assessment
of serum tumor markers (CEA, CA19-9, CA 125, and CA
72.3) every 3 months and with CT scan of abdomen and
thorax every 6 months for 3 years and then every
12 months, for another 2 years. An increase in a tumor
marker C25 % triggered a CT scan for verification of new
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lesions consistent with PMP relapse. Overall survival (OS)
was assessed from registry data up to February 2014. Data
on treatment following relapse was incomplete and indi-
cated individualized approaches used. This is expected to
affect the OS observed probably making this endpoint
poorly associated to the IPC (see ‘‘Results’’ section).
Data Evaluation and Statistics
IC50 was calculated using non-linear regression to a
standard sigmoidal dose–response model in GraphPad
Prism version 5 for Mac (GraphPad Software, San Diego,
CA). Alternatively, sample sensitivity was scored accord-
ing to the SI at the highest cytotoxic drug concentration
used ex vivo. In this case, low drug resistance (LDR) was
defined as a SI below the median, intermediate drug
resistance (IDR) as a SI between the median and median
plus two standard deviations (SDs), and extreme drug
resistance (EDR) as a SI above median plus two SDs based
on all samples investigated ex vivo.16,17
Statistical inferences between several means were per-
formed by one-way ANOVA with Tukey HSD post-hoc
tests. The prognostic importance of clinicopathological
variables and ex vivo drug sensitivity for OS and PFS was
assessed in a Cox regression model. In the model on OS
only univariate results with p\ 0.2 were included in the
final multivariable analysis. Analyses on PFS were adjus-
ted for WHO performance status, histopathological
subtype, and tumor load. The level of significance for all
statistical tests was set to p\ 0.05. Data are presented as
mean ± SD unless otherwise stated.
RESULTS
A successful ex vivo assay fulfilling the quality criteria
was obtained from 92 tumor samples (69 %) and data from
these patients were included for analysis in the study.
Mucin-rich tumor samples, often of the DPAM subtype,
dominated among samples not possible to run in the assay
due to difficulties to recover a sufficient number of
epithelial cells when a lot of mucin was present during cell
preparation. The majority of patients had a histopathology
of DPAM (n = 57), whereas 24 had PMCA and 11 patients
had a PMCA intermediate histology (Table 1). A majority
of patients, 64 %, had previously been treated systemically
and/or locally with chemotherapy for PMP. In 61 patients
(66 %) CC 0–1, i.e., complete cytoreduction was achieved
at CRS. Eighty patients, including 59 of the 61 patients
with complete cytoreduction, received HIPEC, most com-
monly single drug mitomycin C (n = 56), combinations of
cisplatin and doxorubicin (n = 17), or irinotecan and
oxaliplatin (n = 7).
Drug sensitivity varied considerably between patient
samples as indicated by the high SDs observed for the IC50
values for all drugs (Table 2). Samples obtained from
patients previously exposed to cytotoxic drugs were sta-
tistically significantly more resistant to all drugs tested
except irinotecan. There were statistically significant dif-
ferences in drug sensitivity to oxaliplatin, 5-FU, and
cisplatin between the histopathological subtypes of PMP
(Table 2); PMCA showed higher IC50 values for oxali-
platin, 5-FU, and cisplatin compared with samples of
hybrid histology. Similarly, PMCA samples had higher
IC50 for oxaliplatin than DPAM. There were no statistically
significant differences in drug sensitivity between samples
divided into low and high grade according to Bradley
(Supplementary Table 1).18
Analysis of OS according to clinical variables,
histopathology, and drug sensitivity were performed by
uni- and multivariable Cox regression for all patients with
successful ex vivo assay (n = 92; Supplementary Table 2).
Drug sensitivity was not statistically significantly associ-
ated with OS (univariate hazard ratio range, 0.59–1.20),
whereas, as expected, impaired WHO performance status
and completeness of cytoreduction (no vs. yes) were
associated with shorter OS (hazard ratio, 7.93 and 11.73,
respectively; p\ 0.001).
TABLE 1 Clinical characteristics of the pseudomyxoma peritonei
samples successfully analyzed ex vivo (n = 92)
Age, year, mean (range) 56 (24–78)
BMI, kg/m2, mean (range) 25 (19–38)
Male/female 47/45
Histopathology
DPAM 57 (62 %)
PMCA intermediate 11 (12 %)
PMCA 24 (26 %)
Prior chemotherapy
No 59 (64 %)
Yes 33 (36 %)
PCI scorea
1–10 9 (10 %)
11–20 13 (14 %)
21–39 69 (76 %)
WHO performance status
0 79 (86 %)
1–2 13 (14 %)
Complete cytoreductive surgeryb 61 (66 %)
Hyperthermic intraperitoneal chemotherapy 80 (87 %)
DPAM disseminated peritoneal adenomucinosis, PMCA peritoneal
mucinous carcinomatosis, PCI peritoneal carcinoma index, WHO
World Health Organization
a Information on PCI score unavailable in one patient
b CC score 0–1
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Because of the strong prognostic value of complete
cytoreductive surgery, subsequent analyses on prognostic
impact of ex vivo drug sensitivity were performed in
patients with complete cytoreduction (n = 61) with PFS as
the clinical endpoint. Because only five patients in this
group died during follow-up, analysis on OS was not
considered. Following adjustment for performance status,
PCI score, and histopathologic subtype, a strong trend
towards longer PFS was observed for individuals with
tumors sensitive to mitomycin C and cisplatin (p = 0.063
and 0.062, respectively; Table 3).
Because very high concentrations of cytotoxic drugs are
obtained locally when subjects are treated with IPC,
additional analyses on drug sensitivity in relation to PFS
were conducted based on the drug activity, categorized as
LDR, IDR, and EDR, at the highest drug concentration
used ex vivo.15 Following adjustment for patient perfor-
mance status, histopathological subtype, and PCI score, the
general pattern observed was that of a stepwise increase in
risk for disease progression when going from LDR to IDR
and EDR ex vivo sensitivity scores (Table 4). This was
statistically significant for cisplatin and 5FU and margin-
ally so for mitomycin C. The stepwise decrease in PFS
when comparing LDR to IDR and EDR for mitomycin C
and cisplatin is illustrated in Fig. 1.
DISCUSSION
This study investigated the poorly defined role of IPC in
PMP by ex vivo assessment of tumor cell sensitivity in an
assay shown to reflect clinically relevant drug sensitivity in
diagnostic groups as well as in individual patients.14,17,19,20
The number of patients included was quite large for this
uncommon tumor type and OS was strongly associated
with completeness of the CRS and patient performance
status, as expected, indicating that our material and the
findings are representative for PMP.4,5
The fact that the extent of CRS was strongly associated
with OS, whereas ex vivo drug sensitivity was not, points
to the importance of qualified surgery to achieve long-term
survival in PMP. However, ex vivo drug sensitivity pro-
vided prognostic information for PFS and points to a
possible impact of IPC on PFS when added to CRS. These
observations are largely in line with previous findings
pointing to a benefit from HIPEC for PFS but not OS as
well as the possibility to achieve long-term OS with sur-
gery alone.4,5,21–23 Still, a prolongation of PFS from IPC is
considered clinically relevant, because it is reasonably
associated with less disease-related symptoms and, thus,
improved quality of life.
The observations indicating that IPC has limited effect
and require good CRS make sense from a tumor biology
point of view, because the penetrance of cytotoxic drugs
into tumor tissue is very limited. Thus, no substantial effect
of IPC on macroscopic tumor lesions is to be expected.8
Still, some effect from IPC in the presence of remaining
macroscopic disease following CRS cannot be excluded. In
our series, patients without complete CRS who had HIPEC
(n = 21) had a OS of 63 versus 7 months for those who
had not (n = 10), a difference that was statistically sig-
nificant also after adjustment for performance status,
histopathology, and PCI (p = 0.007; not shown). However,
patient selection based on other prognostic factors rea-
sonably explains most of this difference.
Our finding that ex vivo drug sensitivity provided
prognostic information for PFS points to a possible impact
of IPC on PFS when added to CRS. Still, it cannot be
excluded that ex vivo drug sensitivity is only a prognostic
marker reflecting tumor behavior unrelated to a therapeutic
effect from IPC. The only way to differentiate between a
TABLE 2 IC50 values (lM, mean ± standard deviation) for the indicated drugs in the pseudomyxoma peritonei samples (n = 92; IC50 values
available in 88–92 cases depending on cytotoxic drug) according to previous chemotherapy and histopathological subtype












Oxaliplatin 47.2 ± 36.1 25.9 ± 29.4a 30.9 ± 32.0 16.3 ± 12.0 47.9 ± 38.8b,c 33.6 ± 33.5
5FU 708 ± 354 517 ± 431a 591 ± 436 327 ± 256 692 ± 376c 586 ± 414
Mitomycin C 35.0 ± 75.6 12.1 ± 16.8a 22.4 ± 59.6 11.4 ± 19.6 20.0 ± 20.5 20.4 ± 48.3
Doxorubicin 3.3 ± 5.6 1.5 ± 3.0a 2.6 ± 4.9 1.1 ± 2.0 1.5 ± 2.7 2.1 ± 4.2
Irinotecan 410 ± 755 223 ± 311 347 ± 631 1126 ± 78 244 ± 290 291 ± 522
Cisplatin 41.0 ± 35.8 25.6 ± 33.4a 29.8 ± 31.8 13.9 ± 11.7 42.4 ± 45.1c 31.1 ± 34.9
a Statistically significant difference from patients who received preoperative cytotoxic drug treatment, p\ 0.05 by Mann–Whitney U test
b Statistically significant difference from DPAM, p\ 0.05, Kruskal–Wallis followed by Mann–Whitney U test
c Statistically significant difference from PMCA intermediate, p\ 0.05–0.01, Kruskal–Wallis followed by Mann–Whitney U test
Drug sensitivity Testing in Pseudomyxoma Peritonei S813
purely prognostic vs predictive impact from ex vivo drug
sensitivity assessment would be a clinical trial in which
IPC is guided by ex vivo drug sensitivity data.
This would be a way to try to improve the effect of IPC
by individualized selection of active drug(s) but also to
decrease treatment related toxicity by avoiding IPC if no
drugs seem active. The large interindividual sample
differences in drug sensitivity that we observed clearly
point to the potential for IPC individualization. Such trial
would be technically feasible, because tumor tissue for
ex vivo analysis could be obtained by laparoscopy before
the CRS and ex vivo drug sensitivity data can be obtained
within a few days. Such study is presently under discussion
at our center.
Table 3 Univariate and multivariate Cox regression model for
progression-free survival according to dichotomized drug sensitivity
values (below vs. above the median IC50) and clinicopathological
variables in pseudomyxoma peritonei patients with complete cytore-
ductive surgery (n = 61)
Univariate hazard ratio p Multivariate hazard ratioa p
Oxaliplatin 1.33 0.6 0.96 1.0
5-FU 1.24 0.7 0.98 1.0
Mitomycin C 0.66 0.4 0.36 0.063
Doxorubicin 1.49 0.5 1.21 0.8
Irinotecan 0.95 1.0 0.72 0.6
Cisplatin 0.54 0.3 0.36 0.062
a Adjusted for histopathological subtype, PCI score, and WHO performance status
TABLE 4 Univariate and multivariable Cox regression model for progression-free survival according to drug sensitivity at the highest cytotoxic
drug concentration used ex vivo in pseudomyxoma patients with complete cytoreductive surgery (n = 61)
n Univariate hazard ratio p Multivariate hazard ratioa p
Mitomycin C
LDR 35 1 1
IDR 22 2.32 0.2 3.38 0.05
EDR 4 5.19 0.05 6.00 0.05
Cisplatin
LDR 35 1 1
IDR 20 1.86 0.3 3.00 0.064
EDR 4 5.16 0.05 14.35 0.001
Irinotecan
LDR 30 1 1
IDR 26 1.38 0.6 1.53 0.5
EDR 5 1.93 0.5 1.68 0.6
5FU
LDR 30 1 1
IDR 26 0.52 0.3 0.55 0.4
EDR 4 3.83 0.05 4.91 0.05
Oxaliplatin
LDR 33 1 1
IDR 24 0.68 0.7 2.26 0.2
EDR 3 1.28 0.9 3.52 0.3
Doxorubicin
LDR 32 1 1
IDR 20 1.05 1.0 1.03 1.0
EDR 7 1.8 0.4 1.76 0.5
a Adjusted for histopathological subtype, PCI score, and WHO performance status
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Given that standard protocol IPC is currently part of the
standard treatment for PMP, which conclusions can be
drawn from the current study? The PMP samples in this
study were essentially equally drug sensitive as peritoneal
metastasis samples of colorectal cancer analyzed ex vivo
with the same technique.15 Because several of the drugs
analyzed are active in the treatment of colorectal cancer,
similar drug activity also could be expected in PMP, pro-
vided similar drug exposure as in IPC.
The IC50 values for cisplatin and oxaliplatin were almost
identical in the PMP subgroups. Given that a considerably
higher dose of oxaliplatin compared with cisplatin can be
given in IPC, the platinum of choice for IPC in PMP to
achieve maximum effect is suggested to be oxaliplatin.
There were no major differences in drug sensitivity
between the histopathological PMP subtypes, indicating
that IPC protocols for PMP do not need to consider
histopathological subtype. Furthermore, the frequently
observed poor prognosis of PMCA compared with DPAM
seems related to tumor biological factors other than tumor
cell drug sensitivity.
The large interindividual differences in sensitivity to
drugs used in IPC among the PMP samples were substan-
tial. A reasonable interpretation is that IPC may be a more
or less futile treatment step for patients with drug resistant
tumor cells and that these patients would be better off with
CRS alone.
Finally, tumor cells from patients previously exposed to
cytotoxic drugs were generally more drug resistant than
those previously unexposed. This is in line with the clinical
observation that prior chemotherapy was associated with
impaired prognosis in PMP.5 Because systemic chemother-
apy seems not very active in PMP, it might be argued that
PMP patients should go directly to CRS and HIPEC rather
than be started on systemic chemotherapy with the risk for
disease progression and development of drug resistance.6
CONCLUSIONS
Ex vivo assessment of tumor cell sensitivity to cytotoxic
drugs provides prognostic information in PMP and may be
useful for sparing the most resistant patients from IPC
expected to be futile. However, whether selection of drugs
for IPC in PMP based on ex vivo assessment also is pre-
dictive for a treatment effect, and thus could be used for
treatment individualization, needs to be investigated in a
prospective, clinical trial.
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FIG. 1 Progression-free survival in patients with complete cytore-
ductive surgery according to ex vivo sensitivity to mitomycin C and
cisplatin categorized into low drug resistance (LDR), intermediate
drug resistance (IDR), and extreme drug resistance (EDR) at the
highest drug concentration tested ex vivo. Adjusted for patient
performance status, histopathological subtype, and PCI score in a Cox
regression model. For details on number of patients and statistical
significance, see Table 4
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